Rapid Nutrition (ALRPD) H1 2024 earnings summary

Executive summary

• Revenue declined to AUD 276,051 for H1 2024, down from AUD 650,903 year-over-year, due to a strategic restructuring and website relaunch for the flagship brand.

• Net loss widened to AUD 1,986,167 from AUD 915,867 year-over-year, impacted by higher interest, legal, and consultancy expenses related to convertible notes and China market entry.

• Accelerated debt repayment plan is in place, with all convertible notes expected to be repaid by December 2024, ahead of schedule.

• Early success in subscription model adoption, with over 200 customers on monthly plans, supporting future revenue predictability.

Financial highlights

• Gross profit was negative at AUD -294,192, compared to AUD 241,900 in H1 2023.

• Operating loss increased to AUD 1,986,167 from AUD 915,867 year-over-year.

• Cash and cash equivalents rose to AUD 1,025,320 as of June 30, 2024, up from AUD 488,097 at year-end 2023.

• Net cash used in operating activities was AUD -2,175,638, offset by AUD 2,712,861 in financing inflows.

Outlook and guidance

• Management expects sustained revenue growth in H2 2024, driven by the new platform and subscription model.

• Anticipates full repayment of convertible notes by December 2024, reducing future financial obligations.

• Positive market outlook for weight loss and immune health supplements, with global markets projected to expand significantly.